Replies to post #577686 on NorthWest Biotherapeutics Inc (NWBO)

[peeved]

Where do you get this

20 per share news…name 1 buyout that was at even 10x multiple? Let alone 20

[DrHigh]

I assume this is just a gut feeling or did your "source" feed you this info?

[meirluc]

Diver, great if true but on what do you base your beliefs?

[sukus]

Aha.

[ilovetech]

[aesop1]

Come on brother.....20 dollars share? Give me a break

[CaptainObvious]

Wow. Source?

[Judge Smails 40]

Lol - let’s get over 60 cents first….baby steps

[dstock07734]

How did you come up with the number 20?

Merck made $20.9 dollars last year from Keytruda. I don't have the data about keytruda market share in checking point inhibitors in 2022. Keytruda only works for hot tumors which account about 20% of solid tumors. In 2021, keytruda took about %54 of the CI market. DCVax works for all types of solid tumors. Seems the number 20 is far too small.

Recall LP said that there was once a collaboration with BP. But they treated us like beggar and LP had to walk away from the deal. I am guessing most likely that BP was Merck. Why do I think it was Merck?
In July, 2016, Dr. Linda Liau published paper showing that the DCVax-L combined with PD-1 inhibitor was working great on animal model. Then later there was a PR saying that the same combo would be used in a trial on colorectal cancer. But that trial was never materialized.

https://insight.jci.org/articles/view/87059

Merck needs NWBO to maintain its momentum. NWBO doesn't necessarily need Merck to thrive. I would prefer Baker Brothers making huge investment in NWBO.

[Kkhors]

I like dreaming too!

[HappyLibrarian]

As nice as that would be, it never happened.

[mike00h]

Pennies for C-notes. That's probably what Merck offered LP.
Marnix' slide 27 says it all. DCVax will be the heart of a cure.

[Kaizenman]

Thanks for the post. At this point no need entertain offers until final verdict from the USPO on the combo patent. Once this is obtained, then let fun begin on any tendered offers. Sustainable revenue is not far off, relatively speaking. All my opinion.

[Legend431]

Gut feelings don’t do anything for the stock price. Let’s start with a PR

[LessIsMore]

My sources are telling me that Biogen offered $45/share along with a CVR worth up to $13/share contingent on Les Goldman appearing on the Big Booze show and telling the world that UK approval is literally days away.

Fascinating times!

[j e d]

there is zero chance they were offered a $20B deal, where do you get this stuff…

[LessIsMore]

It's shocking to me that Merck wouldn't be buying shares here at 60 cents when they're offering $20/share for the whole Company.

Merck is not very smart, it is no match for the dynamic duo of LP/LG!!

[iclight]

I believe monkeys would fly out of LPs butt before Merck would offer anything for this turd.